Latterell Venture Partners β Full Portfolio
31 tracked investments Β· listed companies and verified rows first
Pulmonx develops the Zephyr Valve, a bronchoscopic device used to treat patients with severe COPD/emphysema without surgery.
BiotechHealthtechMedical DevicesSan Jose, US
LAUREN CRISTINA(Executive Officer)inSri Radhakrishnan(Chief Technology Officer)inMICHAEL BAKER(Executive Officer, Director)inGlendon E. French(Chief Executive Officer and Director)Derrick Sung(Chief Operating Officer and Chief Financial Officer)inGeoffrey Beran Rose(Chief Commercial Officer)
Co-investorsBand of AngelsHealthCapKaiser Permanente VenturesAlly Bridge GroupMontreux Equity Partners
BiotechEvanston, US
Joseph R. Moskal(Chief Scientific Officer)Torsten M. Madsen(Chief Marketing Officer)Ashish Khanna(Secretary & Chief Business Officer)Norbert G. Riedel(Chief Executive Officer)
BoardLiam Ratcliffe(Director)Terry P. Gould(Director)
Co-investorsBain Capital Life SciencesFrazier Life SciencesLongitude CapitalOUP (Osage University Partners)Agent CapitalHBM Healthcare Investments+2 more
Evoke Pharma develops treatments for gastrointestinal disorders, focusing on advancing and commercializing GIMOTI, a nasal spray formulation for diabetic gastroparesis.
BiotechHealthtechMedical Devices
Cam L. Garner(Co-founder and Chairman)Matthew J. D'Onofrio(Co-founder & Chief Executive Officer)
Developed lightweight portable oxygen concentrators; acquired by ResMed.
HealthtechAustin, US
John B. Rush(Executive Officer, Director)Daniel Jensen(Executive Officer)
BoardGeoff Pardo(Director)inStephen M. Salmon(Director)Richard Lin(Director)Roderick A. Young(Director)
Co-investorsGilde Healthcare
Commercializing rapid DNA analysis technology for forensics; acquired by Thermo Fisher Scientific in 2018.
BiotechHardwareMedical Devices
Co-investorsQuestMark Partners
Developed next-generation depression pharmaceuticals; acquired in 2015 for $560M upfront plus milestones.
BiotechEvanston, US
Joseph R. Moskal(Executive Officer)inAmin Khan(Executive Officer)inJames Schulz(Executive Officer)Ronald M. Burch(Executive Officer)Norbert Riedel(Executive Officer, Director)Ashish Khanna(Executive Officer)
Co-investorsCota CapitalEcoR1 CapitalSofinnova VenturesAdams Street Partners
Mereo BioPharma is a rare disease drug developer that funds and advances novel therapeutic candidates not progressed by their originating pharmaceutical or biotech companies, with lead programs in osteogenesis imperfecta and Alpha-1 Antitrypsin Deficiency-associated Lung Disease.
BiotechHealthtech
Co-investorsThe Vertical Group
Viracta Therapeutics was a precision oncology company.
BiotechHealthtechCardiff, US
Co-investorsAisling Capital
Other
Tracked investments with no reachable website or further public details β typically companies that wound down, renamed, or were absorbed.
CalistogaCellective TherapeuticsEnsure MedicalEvokeForteBioForteBio WebsiteMeritageMeritage PharmaOncoMedOncoMed PharmaceuticalsPathwayPathway WebsitePerceptiMedPetrolix WebsiteProteinSimpleProteinSimple WebsiteProteolixRevascular TherapeuticsTetraLogicTetraLogic WebsiteTranscendTranscend WebsiteViracta
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.